Nanjing Luye Sike Pharmaceutical Co., Ltd. clinical trials
Acquired by Luye Pharma Group Ltd., 2007 · source ↗
The registry lists 5 studies whose lead sponsor is Nanjing Luye Sike Pharmaceutical Co., Ltd.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Feb 13, 2020.
Before and after it joined Luye Pharma Group Ltd.
- First submitted before Nanjing Luye Sike Pharmaceutical Co., Ltd. became part of Luye Pharma Group Ltd.
- 0
- First submitted after Nanjing Luye Sike Pharmaceutical Co., Ltd. became part of Luye Pharma Group Ltd.
- 5
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Nanjing Luye Sike Pharmaceutical Co., Ltd.5 studies
Something wrong with this grouping? Tell us on the Luye Pharma Group Ltd. page.
Studies
Recruiting first, then most recently updated. Showing 5 of 5. All Luye Pharma Group Ltd. studies →
- Paclitaxel Liposome for Squamous Non-Small-cell Lung Cancer Study(LIPUSU)Status unknownNCT02996214Phase 4
Sponsor listed in the registry: Nanjing Luye Sike Pharmaceutical Co., Ltd. · First submitted after Nanjing Luye Sike Pharmaceutical Co., Ltd. became part of Luye Pharma Group Ltd.
- Dose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional TreatmentsStatus unknownNCT01994031Phase 4
Sponsor listed in the registry: Nanjing Luye Sike Pharmaceutical Co., Ltd. · First submitted after Nanjing Luye Sike Pharmaceutical Co., Ltd. became part of Luye Pharma Group Ltd.
- Weekly Paclitaxel Liposome Injection Plus Cisplatin in Preoperative Treatment of Breast CancerStatus unknownNCT02142010Not applicable
Sponsor listed in the registry: Nanjing Luye Sike Pharmaceutical Co., Ltd. · First submitted after Nanjing Luye Sike Pharmaceutical Co., Ltd. became part of Luye Pharma Group Ltd.
- Weekly and Every 3 Week Administration of Paclitaxel Liposome Injection in Metastatic Breast CancerStatus unknownNCT02142790Phase 4
Sponsor listed in the registry: Nanjing Luye Sike Pharmaceutical Co., Ltd. · First submitted after Nanjing Luye Sike Pharmaceutical Co., Ltd. became part of Luye Pharma Group Ltd.
- Phase III Study of Vincristine Sulfate Liposome For Injection In Adults With Naïve Acute Lymphoblastic LeukemiaStatus unknownNCT02072785Phase 3
Sponsor listed in the registry: Nanjing Luye Sike Pharmaceutical Co., Ltd. · First submitted after Nanjing Luye Sike Pharmaceutical Co., Ltd. became part of Luye Pharma Group Ltd.